Literature DB >> 19951101

Assessment of serum N-terminal pro-B-type natriuretic peptide concentration for differentiation of congestive heart failure from primary respiratory tract disease as the cause of respiratory signs in dogs.

Mark A Oyama1, John E Rush, Elizabeth A Rozanski, Philip R Fox, Caryn A Reynolds, Sonya G Gordon, Barret J Bulmer, Bonnie K Lefbom, Bill A Brown, Linda B Lehmkuhl, Robert Prosek, Michael B Lesser, Marc S Kraus, Maribeth J Bossbaly, Gregg S Rapoport, Jean-Sebastien Boileau.   

Abstract

OBJECTIVE: To determine whether serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration is useful in discriminating between cardiac and noncardiac (ie, primary respiratory tract disease) causes of respiratory signs (ie, coughing, stertor, stridor, excessive panting, increased respiratory effort, tachypnea, or overt respiratory distress) in dogs.
DESIGN: Multicenter cross-sectional study. ANIMALS: P 115 dogs with respiratory signs. PROCEDURES: Dogs with respiratory signs were solicited for study. Physical examination, thoracic radiography, and echocardiography were used to determine whether respiratory signs were the result of cardiac (ie, congestive heart failure) or noncardiac (ie, primary respiratory tract disease) causes. Serum samples for NT-proBNP assay were obtained at time of admission for each dog. Receiver-operating characteristic curves were constructed to determine the ability of serum NT-proBNP concentration to discriminate between cardiac and noncardiac causes of respiratory signs.
RESULTS: Serum NT-proBNP concentration was significantly higher in dogs with cardiac versus noncardiac causes of respiratory signs. In dogs with primary respiratory tract disease, serum NT-proBNP concentration was significantly higher in those with concurrent pulmonary hypertension than in those without. A serum NT-proBNP cutoff concentration > 1,158 pmol/L discriminated between dogs with congestive heart failure and dogs with primary respiratory tract disease with a sensitivity of 85.5% and a specificity of 81.3%. CONCLUSIONS AND CLINICAL RELEVANCE: Measuring serum NT-proBNP concentration in dogs with respiratory signs helps to differentiate between congestive heart failure and primary respiratory tract disease as an underlying cause.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19951101     DOI: 10.2460/javma.235.11.1319

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  9 in total

1.  Association between Survival Time and Changes in NT-proBNP in Cats Treated for Congestive Heart Failure.

Authors:  K V Pierce; J E Rush; L M Freeman; S M Cunningham; V K Yang
Journal:  J Vet Intern Med       Date:  2017-03-31       Impact factor: 3.333

2.  ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs.

Authors:  Bruce W Keene; Clarke E Atkins; John D Bonagura; Philip R Fox; Jens Häggström; Virginia Luis Fuentes; Mark A Oyama; John E Rush; Rebecca Stepien; Masami Uechi
Journal:  J Vet Intern Med       Date:  2019-04-11       Impact factor: 3.333

Review 3.  Coughing in Small Animal Patients.

Authors:  Brisa M Hsieh; Alicia K Beets
Journal:  Front Vet Sci       Date:  2020-01-21

4.  Analysis of Therapeutic Effect of Elderly Patients with Severe Heart Failure Based on LSTM Neural Model.

Authors:  Shunhong Chen; Shoudu He
Journal:  Comput Intell Neurosci       Date:  2022-08-28

5.  Plasma atrial natriuretic peptide and N-terminal pro B-type natriuretic peptide concentrations in dogs with right-sided congestive heart failure.

Authors:  Nobuyuki Kanno; Yasutomo Hori; Yuichi Hidaka; Seishiro Chikazawa; Kazutaka Kanai; Fumio Hoshi; Naoyuki Itoh
Journal:  J Vet Med Sci       Date:  2015-11-26       Impact factor: 1.267

6.  Relationship of plasma N-terminal pro-brain natriuretic peptide concentrations to heart failure classification and cause of respiratory distress in dogs using a 2nd generation ELISA assay.

Authors:  P R Fox; M A Oyama; M J Hezzell; J E Rush; T P Nguyenba; T C DeFrancesco; L B Lehmkuhl; H B Kellihan; B Bulmer; S G Gordon; S M Cunningham; J MacGregor; R L Stepien; B Lefbom; D Adin; K Lamb
Journal:  J Vet Intern Med       Date:  2014-10-10       Impact factor: 3.333

7.  Breed differences in natriuretic peptides in healthy dogs.

Authors:  K Sjöstrand; G Wess; I Ljungvall; J Häggström; A-C Merveille; M Wiberg; V Gouni; J Lundgren Willesen; S Hanås; A-S Lequarré; L Mejer Sørensen; J Wolf; L Tiret; M Kierczak; S Forsberg; K McEntee; G Battaille; E Seppälä; K Lindblad-Toh; M Georges; Hannes Lohi; V Chetboul; M Fredholm; K Höglund
Journal:  J Vet Intern Med       Date:  2014-02-03       Impact factor: 3.333

8.  Prognostic factors in dogs with presumed degenerative mitral valve disease attending primary-care veterinary practices in the United Kingdom.

Authors:  M J Mattin; A Boswood; D B Church; D C Brodbelt
Journal:  J Vet Intern Med       Date:  2018-10-24       Impact factor: 3.333

9.  Evaluation of plasma N-terminal pro-B-type natriuretic peptide levels in healthy North American Salukis with normal echocardiographic measurements.

Authors:  Christopher Brennan; Tamilselvam Gunasekaran; Robert A Sanders
Journal:  PLoS One       Date:  2022-01-31       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.